Currently out of the existing stock ratings of Carter Gould, 122 are a BUY (54.95%), 76 are a HOLD (34.23%), 24 are a SELL (10.81%).

Carter Gould

Work Performance Price Targets & Ratings Chart

Analyst Carter Gould, currently employed at BARCLAYS, carries an average stock price target met ratio of 70.15% that have a potential upside of 26.7% achieved within 227 days.

Carter Gould’s has documented 457 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NBIX, Neurocrine Biosciences at 23-Dec-2024.

Wall Street Analyst Carter Gould

Analyst best performing recommendations are on APLT (APPLIED THERAPEUTICS).
The best stock recommendation documented was for APLT (APPLIED THERAPEUTICS) at 3/21/2022. The price target of $2.5 was fulfilled within 3 days with a profit of $0.67 (36.61%) receiving and performance score of 122.04.

Average potential price target upside

of $88.24 (14.92%) on REGN (REGENERON PHARMACEUTICALS).
of $44.1 (17.45%) on LLY (ELI LILLY AND COMPANY).
of $19.08 (26.62%) on INCY (YTE).

ABBV AbbVie ALLK Allakos AMGN Amgen APLT Applied Therapeutics BIIB Biogen BMY Bristol-Myers Squibb Company CYTK Cytokinetics GILD Gilead Sciences LLY Eli Lilly and Company MRK Merck mpany NBIX Neurocrine Biosciences PFE Pfizer REGN Regeneron Pharmaceuticals TVTX Travere Therapeutics XLRN Acceleron Pharma GOSS Gossamer Bio RETA Reata Pharmaceuticals ALEC Alector CELG Celgene MTEM Molecular Templates VOR Vor Biopharma ACLX Arcellx ESPR Esperion Therapeutics INCY yte VRTX Vertex Pharmaceuticals SKIL Skillsoft Corp.

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Christopher Raymond (PIPER SANDLER)